What Strykagen does

Strykagen Corp is a pre-clinical biopharmaceutical company developing therapeutics and diagnostics for rare, life-threatening muscle diseases, primarily Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Merosin-deficient congenital muscular dystrophy (MDC1A), and Limb Girdle Muscular Dystrophy 2I (LGMD2I). Founded in 2013 and headquartered at the University of Nevada School of Medicine in Reno, the company operates as a small founder-led team (1-10 employees) that has exclusively licensed worldwide patent-pending technologies from the University of Nevada, Reno.

Strykagen's core technology is centered on α7β1 integrin targeting, leveraging a proprietary muscle cell-based assay combined with quantitative high-throughput screening (qHTS) of more than 400,000 compounds to identify therapeutic candidates. Its lead asset, Stryka-969 (S-969), is an orally bioavailable small molecule demonstrated in preclinical models to upregulate α7β1 integrin and improve muscle strength. The broader pipeline includes integrin-enhancing biologics (AAV-mediated gene transfer and laminin-111 protein therapy) and non-invasive diagnostic tests and biomarkers for disease diagnosis, prognosis, and therapeutic monitoring. The company holds Orphan Drug Designation across its muscular dystrophy indications.

The business model is pre-revenue and predicated on advancing candidates through preclinical and clinical milestones for eventual worldwide licensing, milestone payments, and royalties, or outright acquisition by a larger pharmaceutical company with rare disease commercialization capabilities. R&D is currently funded by a $958,973 NIH SBIR Phase 2 grant awarded in September 2023 to support IND-enabling studies for S-969, supplemented by founder equity and academic partnerships. Go-to-market is enterprise-focused, targeting pharmaceutical partners rather than direct patient or provider channels.

Name

Strykagen

Legal name

Strykagen Corp.

Website

https://strykagen.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Strykagen Corp is a pre-clinical biopharmaceutical company developing orally bioavailable small molecule therapeutics and non-invasive diagnostics targeting α7β1 integrin for rare muscle diseases including Duchenne and Becker muscular dystrophy.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF)

akta.pro secondary industries

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Rare disease therapeutics
• Muscular dystrophy treatments
• Small molecule drug discovery
• Integrin therapy
• Biopharmaceutical diagnostics

Headquarters

HQ city

Reno

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Therapeutic Licensing/Acquisition: Pre-revenue company. Business model focused on developing therapies through clinical stages and securing licensing agreements or acquisition by larger pharmaceutical companies. Revenue will be generated through licensing royalties, milestone payments, and eventual product commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Strykagen is a pre-clinical biopharmaceutical company developing transformative therapeutics and diagnostics for life-threatening rare muscle diseases, including Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD), Limb Girdle Muscular Dystrophy 2I (LGMD2I), and Merosin-deficient congenital muscular dystrophy (MDC1A). Its lead candidate Stryka-969 (S-969) is an orally bioavailable small molecule identified through quantitative high-throughput screening (qHTS) of over 400,000 compounds using a proprietary α7β1 integrin muscle cell-based assay. The company also pursues integrin-enhancing biologics, non-invasive diagnostics, and biomarkers for muscular dystrophy.

Product overview

Strykagen is a biopharmaceutical company developing a portfolio of therapeutics and diagnostics for rare muscle diseases. The core product offerings include Stryka-969 (S-969), an orally delivered small molecule therapeutic targeting α7β1 integrin for Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Merosin deficient congenital muscular dystrophy (MDC1A), and Limb Girdle Muscular Dystrophy 2I (LGMD2I); integrin enhancing biologics and small molecule therapeutics; and non-invasive diagnostic tests and biomarkers for muscular dystrophy diagnosis and prognosis. The company leverages patent-pending technologies licensed worldwide from the University of Nevada, Reno that stabilize the myomatrix and prevent muscle disease progression.

Differentiator

Problem solved

Functional benefit

Products and services

• Stryka-969 (S-969) Small Molecule Therapeutic An orally delivered small molecule therapeutic identified using a novel α7β1 integrin muscle cell-based assay and qHTS technology screening over 400,000 compounds. It increases α7β1 integrin in DMD patient muscle cells and has been shown to increase muscle strength in preclinical studies. Targeted at DMD, BMD, LGMD2I, and MDC1A patients.
• Integrin Enhancing Therapeutics Novel biologic and small molecule therapeutics targeting α7β1 integrin for the treatment of muscular dystrophy, including AAV-mediated gene transfer of α7 or β1D integrin and laminin-111 protein therapy. Designed to stabilize muscle membrane, prevent muscle damage, and promote muscle regeneration.
• Non-Invasive Diagnostic Tests Non-invasive diagnostic tests developed to assist in the diagnosis and prognosis of muscular dystrophy. Targeted at clinicians and patients with suspected or confirmed muscular dystrophy.
• Biomarkers for Muscular Dystrophy Biomarker development for muscular dystrophy to assist in disease diagnosis, prognosis, and therapeutic monitoring. Used by clinicians and researchers tracking disease progression and treatment response.

Quantifiable outcome

• Improved muscle strength in preclinical models of muscular dystrophy
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• University of Nevada, RenocoreStrategic or Co-development PartnerStrykagen operates within the University Nevada School of Medicine and has exclusively licensed patent-pending technologies from the university. The partnership provides research laboratory space and institutional support for the company's drug discovery activities.
• Sarcomatrix TherapeuticscoreStrategic or Co-development PartnerSarcomatrix Therapeutics is identified as a research partner of Strykagen. The partnership involves collaboration on S-969 small molecule development for muscle wasting diseases, supported by NIH SBIR grant funding.
• Patient Advocacy OrganizationsminorStrategic or Co-development PartnerRelationships with patient advocacy groups supporting muscular dystrophy research. These organizations provide community engagement, disease awareness support, and potential collaboration on clinical trial development.
• Academic InstitutionsminorStrategic or Co-development PartnerCollaborative relationships with academic institutions for research purposes, providing access to additional scientific expertise and research capabilities beyond the University of Nevada affiliation.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Sarepta Therapeutics: Commercial-stage leader in DMD therapeutics with approved exon-skipping therapies (Exondys 51, Vyondys 53, Amondys 45) and the Elevidys gene therapy. Directly competes with Strykagen in the DMD therapeutic space with a more advanced pipeline and substantial commercial infrastructure.
• PTC Therapeutics: Rare disease biopharmaceutical company with Translarna (ataluren) approved for DMD nonsense mutations and an active pipeline in muscular dystrophy and related rare disorders. Direct competitor in DMD therapeutics with comparable Orphan Drug-focused business model.
• Solid Biosciences: Clinical-stage biotechnology company developing gene therapies and other treatments for Duchenne muscular dystrophy. Direct competitor pursuing AAV-mediated gene therapy approaches that overlap with Strykagen's integrin enhancement gene therapy platform.
• Capricor Therapeutics: Clinical-stage biotechnology company developing cell therapy (CAP-1002) and exosome-based treatments for DMD and other rare diseases. Direct competitor in the DMD therapeutic space with a complementary cell-based modality.
• Edgewise Therapeutics: Clinical-stage company developing oral small molecule therapeutics for muscular dystrophies including DMD and Becker muscular dystrophy. Most direct peer in terms of therapeutic modality (oral small molecules) and disease focus, competing for similar patient populations and partnership opportunities.
• Sarcomatrix Therapeutics: Research partner of Strykagen with shared focus on small molecule development for muscle wasting diseases (S-969 program). Closely aligned collaborator with overlapping scientific approach and joint NIH SBIR grant funding.

Emerging players

• Dyne Therapeutics: Clinical-stage company developing oligonucleotide-based therapies for muscle diseases including DMD and DM1. Emerging player with overlapping therapeutic modality focus (targeted delivery to muscle) and similar rare disease commercial model.
• Lexeo Therapeutics: Clinical-stage gene therapy company with programs in DMD and other rare genetic diseases including cardiac and central nervous system disorders. Emerging player pursuing AAV-mediated gene therapy in overlapping indications.
• Catabasis Pharmaceuticals: Biopharmaceutical company developing small molecule therapeutics for DMD and other rare diseases. Emerging player with comparable therapeutic modality (small molecules) and disease focus, representing a relevant peer for capital markets and partnership benchmarking.

Broad incumbents

• BioMarin Pharmaceutical: Established rare disease biopharmaceutical company with multiple approved enzyme replacement and gene therapies. Broad incumbent in rare disease therapeutics with the commercial scale, manufacturing, and regulatory capabilities that represent Strykagen's likely acquisition/partner profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/strykagen-corp.

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strykagen